Cue Biopharma
CUE
75 hedge funds and large institutions have $35M invested in Cue Biopharma in 2022 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 29 increasing their positions, 25 reducing their positions, and 33 closing their positions.
16% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 25
0.38% less ownership
Funds ownership: 1.8% → 1.42% (-0.38%)
8% less call options, than puts
Call options by funds: $160K | Put options by funds: $173K
25% less funds holding
Funds holding: 100 → 75 (-25)
61% less capital invested
Capital invested by funds: $89.2M → $35M (-$54.2M)
64% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 33
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.88M |
| 2 |
MAM
Monaco Asset Management
Monaco
|
+$1.56M |
| 3 |
Morgan Stanley
New York
|
+$924K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$747K |
| 5 |
CC
Carlson Capital
Dallas,
Texas
|
+$682K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$8.36M |
| 2 |
BlackRock
New York
|
-$6.04M |
| 3 |
State Street
Boston,
Massachusetts
|
-$2.22M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$976K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$951K |
CUE Hedge Fund Activity: Q2 2022 in Review
75 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Cue Biopharma (CUE) for Q2 2022, worth a combined $35M — down 61% from $89.2M a quarter earlier.
Sellers outnumbered buyers: 33 funds closed out of CUE and 12 opened new positions — a net loss of 21 holders — while 25 trimmed existing stakes and 29 added.
The largest buyer was Millennium Management, adding an estimated $1.88M. The largest seller was Nantahala Capital Management, cutting an estimated $8.36M.
- 75 institutional investors held Cue Biopharma (CUE) as of Q2 2022, down from 100 in Q1 2022.
- Funds reported $35M of Cue Biopharma stock for Q2 2022, down 61% quarter-over-quarter.
- 12 funds opened new Cue Biopharma positions in Q2 2022 and 33 closed out, a net change of -21 holders.
- The largest Cue Biopharma buyer in Q2 2022 was Millennium Management, an estimated $1.88M added.
- The largest Cue Biopharma seller in Q2 2022 was Nantahala Capital Management, an estimated $8.36M sold.
Based on aggregated 13F filings for Q2 2022.